# Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

> **NCT06627478** · PHASE1 · COMPLETED · sponsor: **Xentria, Inc.** · enrollment: 114 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** NKF-INS(G)
- **DRUG:** US-Lantus®
- **DRUG:** EU-Lantus®

## Key facts

- **NCT ID:** NCT06627478
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-29
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06627478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06627478, "Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06627478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*